artemisinin-based combination therapies (ACTs)
GPTKB entity
Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antimalarial therapy
|
| gptkbp:contains |
artemisinin derivative
partner drug |
| gptkbp:contraindication |
hypersensitivity to artemisinin
|
| gptkbp:effect |
gptkb:Plasmodium_falciparum
|
| gptkbp:example |
gptkb:artesunate-amodiaquine
gptkb:artesunate-mefloquine gptkb:artesunate-sulfadoxine-pyrimethamine gptkb:dihydroartemisinin-piperaquine gptkb:artemether-lumefantrine |
| https://www.w3.org/2000/01/rdf-schema#label |
artemisinin-based combination therapies (ACTs)
|
| gptkbp:introducedIn |
2000s
|
| gptkbp:mechanismOfAction |
rapid parasite clearance
|
| gptkbp:partnerDrugPurpose |
eliminates residual parasites
prevents resistance |
| gptkbp:recommendation |
gptkb:World_Health_Organization
|
| gptkbp:reduces |
malaria transmission
malaria mortality |
| gptkbp:resistanceReported |
gptkb:Southeast_Asia
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
vomiting anorexia dizziness headache |
| gptkbp:usedFor |
treatment of malaria
|
| gptkbp:bfsParent |
gptkb:dihydroartemisinin
|
| gptkbp:bfsLayer |
6
|